



**JLN's Domestic Resource Mobilization Collaborative**  
*COVID-19 Vaccine Financing: A Domestic Resource Mobilization Perspective*

# Landscaping of COVID19 and vaccines

From production, and registration to distribution  
29 April 2020

**Supported by:**




JAPAN GOV  
THE GOVERNMENT OF JAPAN

BILL & MELINDA  
GATES foundation




## WHO Coronavirus (COVID-19) Dashboard

[Overview](#)[Data Table](#)[Explore](#)

Globally, as of **2:08pm CEST, 28 April 2021**, there have been **148,128,030 confirmed cases** of COVID-19, including **3,124,905 deaths**, reported to WHO. As of **27 April 2021**, a total of **961,231,417 vaccine doses** have been administered.

# Global Situation Overview (as of 27 April 2021)

- **Previous 24 hours:**
  - 534,598 new confirmed cases.
  - 7,259 new deaths.
- **Cumulative:**
  - 147,377,159 confirmed cases.
  - 3,112,041 deaths.




*data smoothed with 7-day moving average*

Countries with the highest number of new cases in previous 24 hours

Country	New Cases	Total Cases	New Deaths	Total Deaths
India	323,144	17,636,307	2,771	197,894
Turkey	38,553	4,629,969	347	38,358
United States of America	34,469	31,742,914	302	566,842
Brazil	32,572	14,340,787	1,305	390,797
France	22,849	5,413,036	153	102,184
Iran (Islamic Republic of)	21,026	2,417,230	496	70,070
Colombia	17,190	2,774,464	465	71,351
Argentina	15,012	2,860,884	170	61,644
Italy	13,157	3,962,674	217	119,238
Germany	11,907	3,299,325	60	81,624

# COVID19 vaccine roll out globally




Globally, as of 2:08pm CEST, 28 April 2021, there have been 148,128,030 confirmed cases of COVID-19, including 3,124,905 deaths, reported to WHO. As of 27 April 2021, a total of 961,231,417 vaccine doses have been administered.

# From production, registration, planning, funding to distribution

## The long road to vaccination

Ensuring equitable distribution to the last mile requires specific interventions at each stage of deployment, constant monitoring, and continuous adaptation




Delivery of COVID19 vaccines presents challenges unprecedented in scale, speed and specificities

## NDVPs and WHO/WBG Readiness Assessment: 10 Core Areas of Assessments

1. Planning & Coordination
2. Resources & Funding
3. Regulation
4. Prioritization, Targeting & Surveillance
5. Service Delivery
6. Training & Supervision
7. Monitoring & Evaluation
8. Cold Chain & Logistics
9. Safety Surveillance
10. Demand Generation & Communication

# R&D Pipeline

(14 April)



# WHO EUListed


Manufacturer/ Developer	Vaccine Type	Common Name	Brand Name
Pfizer/BioNTech	mRNA	Tozinameran-COVID-19 mRNA Vaccine	COMINARTY®
AZ/Serum Institute of India	Viral Vector	COVID-19 Vaccine (ChAdOx1-S ([recombinant]))	COVISHIELD™
AZ/SK Bioscience	Viral Vector	COVID-19 Vaccine (ChAdOx1-S ([recombinant]))	None
Janssen (J&J)	Viral Vector	COVID-19 Vaccine (Ad26.COV2-S [recombinant])	None
<b>*Univ of Oxford/AZ</b>	<b>Viral Vector</b>	<b>COVID-19 Vaccine (ChAdOx1-S ([recombinant]))</b>	<b>*Vaxzevria</b>

\*same COVID-19 vaccine approved by EMA was WHO EUListed on 15 April with alternative manufacturing sites as follows: Catalent Anagni (Italy), CP Pharmaceuticals (UK), IDT Biologika (Germany) and SK Bio (Rep of Korea)

Under review	Developer/ Manufacturer	Timeline to issue decision
	Sinopharm/Beijing Institute-	End April 2021
	Sinovac	May 2021
	Gamaleya	Under review, No date yet, to be confirmed Joint inspection with EMA in May or June
	Cansino	No date yet, to be confirmed
	Moderna	End of April
	Novavax	Under review No date yet.



# Production by type of vaccines

Source: Affinity, IFPMA




# Inequity is decreasing, but high income countries have administered 100x more doses per inhabitant than the lowest income countries

Cumulative COVID-19 doses administered per 100 population





# WPRO COVID-19 Vaccine Access and Availability



Note: Except for Sinovac, manufacturers in China do not disclose the no. of doses supplied to CHN.  
Data as of 28. 4. 2021

# COVAX Allocation Overview

COVAX announced 3<sup>rd</sup> allocation round on Monday (14m doses Pfizer)

	Round #1	Round #2	Round #3
Announced	3 February	2 March	12 April
Period	February-March	January-May	April-June
Vaccine & Number of doses	Pfizer 1.2M doses	SII & AZ/SK Bio 237M doses	Pfizer 14M doses
Number of participants	18 participants	142 participants: 60 SII; 82 AZ/SK Bio	47 participants

Pfizer (3<sup>rd</sup> round) Doses for WPR Countries (April to June)

Country	Doses Allocated
Australia	15%
Lao PDR	3%
Mongolia	3%
Philippines	68%
New Zealand (SFP)	3%
Republic of Korea (SFP/UNICEF)	9%
<b>Total</b>	<b>Nearly 3,5 mil doses</b>